ArticleJournal of virology2026
Argininosuccinate synthase 1 (ASS1) orchestrates arginine metabolism and ornithine production to modulate CHIKV infection.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Viruses reprogram the host metabolic machinery to ensure a continuous supply of macromolecules and energy for their own survival. Important cellular pathways are impacted during infection, resulting in changes in key metabolic precursors that influence infection outcomes. The present study was undertaken to evaluate the impact of L-arginine and argininosuccinate synthase 1 (ASS1), an important upstream enzyme of the arginine metabolism pathway, during chikungunya virus (CHIKV) infection in the human liver-derived Huh-7 cells. Using dose-dependent and time-course L-arginine supplementation experiments, we demonstrated that CHIKV exploits cellular arginine for enhanced viral replication. Loss-of-function and gain-of-function studies of ASS1, combined with nitric oxide donor treatments, revealed that arginine metabolism influences multiple downstream pathways, including ornithine synthesis, proline metabolism, and nitric oxide production during CHIKV infection. We further examined the relationship between ASS1 expression and STAT3 signaling in the context of viral infection. Our results demonstrate that exogenous L-arginine supplementation and ASS1 overexpression enhance CHIKV replication in Huh-7 cells. Conversely, ASS1 silencing resulted in >95% reduction in viral titers. Mechanistically, ASS1 modulated arginase 1 activity, affecting ornithine production and downstream metabolites while also influencing the cellular nitroso-redox environment. Additionally, ASS1 expression affected STAT3 levels and its subcellular localization: ASS1 overexpression correlated with reduced nuclear STAT3 accumulation and increased viral replication, whereas ASS1 depletion promoted STAT3 nuclear translocation and restricted viral infection. These findings reveal a complex interplay between arginine metabolism, innate immune signaling, and CHIKV replication, identifying ASS1 as a potential regulatory node in CHIKV-host interactions. IMPORTANCE: Metabolic reprogramming of the host is crucial for the virus to establish itself within the cell, and in this process, the virus hijacks several host metabolic pathways. We examined the role of an important arginine metabolizing enzyme, human argininosuccinate synthase (ASS1), during CHIKV infection in liver cells through silencing and overexpressing ASS1 and by L-arginine supplementation. We demonstrate that ASS1 favors CHIKV replication and also plays important roles in several downstream cellular processes during virus infection. This study further deepens our understanding of the significance of the crucial metabolites involved in the arginine metabolism pathway during CHIKV infection and how CHIKV exploits the specific pathway to enhance its replication.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.